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A B S T R A C T
Morphine-3-glucuronide (M3G), the main metabolite of morphine, has been implicated in the development of
tolerance and of opioid-induced hyperalgesia, both limiting the analgesic use of morphine. We evaluated the
acute and chronic effects of M3G and morphine as well as development of antinociceptive cross-tolerance be-
tween morphine and M3G after intrathecal administration and assessed the expression of pain-associated neu-
rotransmitter substance P in the spinal cord. Sprague-Dawley rats received intrathecal M3G or morphine twice
daily for 6 days. Nociception and tactile allodynia were measured with von Frey filaments after acute and
chronic treatments. Substance P levels in the dorsal horn of the spinal cord were determined by im-
munohistochemistry after 4-day treatments. Acute morphine caused antinociception as expected, whereas acute
M3G caused tactile allodynia, as did both chronic M3G and morphine. Chronic M3G also induced antinociceptive
cross-tolerance to morphine. M3G and morphine increased substance P levels similarly in the nociceptive la-
minae of the spinal cord. This study shows that chronic intrathecal M3G sensitises animals to mechanical sti-
mulation and elevates substance P levels in the nociceptive laminae of the spinal cord. Chronic M3G also induces
antinociceptive cross-tolerance to morphine. Thus, chronic M3G exposure might contribute to morphine-induced
tolerance and opioid-induced hyperalgesia.
1. Introduction
Opioids are used to treat moderate-to-severe acute and chronic pain
but adverse effects such as respiratory depression, nausea, somnolence,
dependence, tolerance and opioid-induced hyperalgesia limit their use
(Kalso et al., 2004; Rivat and Ballantyne, 2016; Roeckel et al., 2016). In
humans, morphine is mainly metabolised to morphine-3-glucuronide
(M3G) and morphine-6-glucuronide by hepatic UDP-glucuronosyl-
transferase 2B7 (Coffman et al., 1997). However, rats form only M3G
(Coffman et al., 1997; Coughtrie et al., 1989). M3G has excitatory ef-
fects (Hemstapat et al., 2009; Komatsu et al., 2016; Suzuki et al., 1993)
and it has been proposed to be partly responsible for morphine toler-
ance and opioid-induced hyperalgesia (Ekblom et al., 1993; Smith and
Smith, 1995). M3G has low affinity (Mignat et al., 1995) to and may be
a partial and biased agonist at the μ receptor (Roeckel et al., 2017).
Therefore, a high central nervous system concentration of M3G is
needed for a clinically significant μ receptor mediated effect. As a polar
molecule, M3G should not cross the blood-brain barrier to a large ex-
tent (Bickel et al., 1996). However, in long-term administration, four
times higher concentrations of M3G than morphine have been mea-
sured in the cerebrospinal fluid of patients receiving high doses of
morphine (Goucke et al., 1994). We are not aware of studies that would
have assessed the effects of chronic M3G treatment on the development
of opioid tolerance and tactile allodynia. Morphine is known to increase
substance P levels and activate glial cells (King et al., 2005; Ma et al.,
2001; Raghavendra et al., 2002), but the effects of M3G are not known.
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Our aim was to assess whether chronic M3G treatment can sensitise
rats to a mechanical stimulus and whether M3G may cause morphine
tolerance independent of morphine. We evaluated the development of
antinociceptive cross-tolerance between morphine and M3G after in-
trathecal administration and assessed glial activation and substance P
levels in the spinal cord.
2. Materials and methods
2.1. Animals
Experiments were approved by the Southern Finland Regional State
Administrative Agency (ESAVI-9697/04.10.07-2017). We followed the
ethical guidelines of the International Association for the Study of Pain
(Zimmermann, 1983) and the EU2010/63 legislation with adherence to
the ARRIVE guidelines. Adult male Sprague-Dawley rats (180–250 g)
were housed in clear plastic cages in temperature- and light-controlled
rooms (23 ± 2 °C and light cycle of 12 h). Food and water were
available ad libitum. Before experiments, the animals were habituated to
the experimental environment for 5 days, 2 h daily. After intrathecal
catheterisation, the animals were housed individually. After the ex-
periments, animals were deeply anaesthetised and euthanised. The
number of animals in experimental groups was kept as small as possible
(Zimmermann, 1983), but high enough to reach significant statistical
power.
2.2. Drugs
Morphine hydrochloride, ketamine hydrochloride (Ketaminol vet®,
Intervet, Boxmeer, Netherlands), lidocaine hydrochloride (Lidocain®,
Orion Pharma, Espoo, Finland), and medetomidine hydrochloride
(Domitor®, Orion Pharma) were purchased from the University
Pharmacy (Helsinki, Finland). Morphine 3-β-D-glucuronide was a kind
gift from the National Institute of Drug Abuse (Bethesda, MD, USA).
Morphine and M3G were dissolved in physiological 0.9% saline.
Intrathecal drugs were administered in a volume of 10 μl followed by a
flush of 15 μl saline. The choice of the intrathecal test dose of morphine
was based on a previous study where acute administration of 1.5 μg of
morphine caused significant antinociception (Lilius et al., 2012) but
tolerance developed to the same dose after a 4-day exposure to in-
trathecal morphine. The threefold higher (5 μg intrathecal) dose of
M3G was based on our unpublished pilot studies where this dose pro-
duced significant nociception and on clinical data (Goucke et al., 1994)
where four times higher concentrations of M3G than morphine could be
measured from cerebrospinal fluid.
2.3. Intrathecal catheter implantation
Rats were anaesthetised with subcutaneous ketamine (50 mg/kg)
and medetomidine (0.4 mg/kg). After verifying the absence of a reac-
tion to paw pinch, the animal was placed on a stereotactic frame. The
cisterna magna was surgically exposed as earlier described (Yaksh and
Rudy, 1976). An 8-cm 26G intrathecal catheter (0.36 mm outer dia-
meter, 0.18 mm inner diameter, item no. 0007740, Alzet, Durect, Cu-
pertino, CA, USA) was carefully inserted into the subarachnoid space to
the lumbar enlargement area level through the cisterna magna. The
cannula was sutured to neck muscles and the wound was closed with
5–0 sutures. The catheter was filled with 15 μl of saline and the tip
closed by cauterisation. After recovery for 3–4 days, the correct pla-
cement of the catheter was confirmed with 15 μl (20 mg/ml) of lido-
caine, followed by a flush of 15 μl saline. Only rats showing reversible
symmetrical paralysis of the hind limbs were accepted for experiments.
2.4. Behavioural testing
Von Frey testing for tactile allodynia and mechanical nociception
was conducted with nine different calibrated monofilaments (2, 4, 6, 8,
10, 15, 26, 60 and 100 g, North Coast Medical, Morgan Hill, CA, USA)
in ascending order. The hind paws of the rats standing on a metal mesh
covered with a plastic dome were stimulated 5 times with each filament
with 1-min intervals. Von Frey data are presented with the percent
response method (Deuis et al., 2017) as the sum of withdrawal re-
sponses (0–5) and summed up separately for thin filaments (2–15 g), for
the assessment of tactile allodynia, and thick (26–100 g) filaments, for
assessing nociception. Maximum summed response rate is therefore 30
for thin and 15 for thick filaments. When an animal responded five
times out of five to a certain force, the rest of the thicker filaments were
registered as eliciting a maximum response for the particular time
point.
2.5. Immunohistochemistry
Spinal cord samples were collected from the lumbar enlargement
(T13–L5) after transcardial perfusion with 4% paraformaldehyde (PFA).
PFA-fixed samples were embedded to paraffin blocks, sectioned to
10 μm slices, and probed with antibodies for ionized calcium-binding
adapter molecule 1 (IBA1) (1:1000, Cat N 019–19741, Wako Richmond,
VA, USA), glial fibrillary acidic protein (GFAP) (1:400, Cat G-3893,
Sigma-Aldrich, St. Louis, MO, USA) or substance P (1:10,000, Cat No. T-
4107, Peninsula Laboratories, CA, USA). Secondary antibodies, con-
jugated with horseradish peroxidase and DAB as a substrate were used
to visualise bound primary antibodies (DAB peroxidase substrate kit,
Vector Laboratories, CA, USA). Slides were scanned with 3DHISTEC
(3DHISTECH, Budapest, Hungary) in the core facility of the University
of Helsinki (https://www.fimm.fi/en/services/technology-centre/
digital-and-molecular-pathology-unit). Nociceptive laminae (I, II and
V) of the spinal cord were cropped with Panoramic Viewer (3DHISTEC)
and CorelDraw X8 (Corel Corporation, ON, Canada) using a spinal cord
model figure (Paxinos and Watson, 1998). Two samples per animal
were analysed and the average used. The number of IBA1 or GFAP
positive cells and area of staining of IBA1, GFAP and substance P were
quantified with Matlab R2014b (Mathworks, Natick, MA, USA) as
previously described (Jokinen et al., 2018).
2.6. Experiment 1: effects of chronic intrathecal morphine and M3G on
tactile allodynia and antinociceptive tolerance
On the first day, opioid-naïve rats received either an intrathecal test
dose of 1.5 μg morphine or 5 μg M3G (Fig. 1). The treatment was
continued twice daily with 12-h intervals with the same drug with the
Fig. 1. Intrathecal drug treatment scheme from the
first day to the morning of the seventh day in the
chronic morphine and chronic morphine-3-glucur-
onide (M3G) treatment groups. Behavioural testing
was conducted in the morning of day 1 after acute
morphine (1.5 μg) or M3G (5 μg), in the morning of
day 6 after chronic treatments (morphine 15 μg or
M3G 5 μg) and after an acute dose of morphine
(1.5 μg), and in the morning of day 7 after chronic
treatments and acute dose of morphine (5 μg).
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exception that the morphine dose was increased to 15 μg. In the
morning of day 6, both groups received 1.5 μg of intrathecal morphine
to test for possible antinociceptive tolerance and cross-tolerance or
hyperalgesia. Twelve h later, animals received their chronic treatment
(morphine 15 μg or M3G 5 μg) and in the morning of day 7, both groups
received a higher 5 μg dose of morphine. Behavioural testing (von Frey)
was conducted on days 1 (acute effects of morphine or M3G), 6 (mor-
phine 1.5 μg), and 7 (morphine 5 μg) before and 30, 60, and 120 min
after the test dose.
2.7. Experiment 2: effects of chronic intrathecal morphine and M3G on glial
activation and substance P expression in the spinal cord
To assess the possible actions of morphine and M3G on substance P
or glial marker expression, a second group of rats was treated with
intrathecal M3G (5 μg), morphine (15 μg) or saline twice a day with 12-
h intervals. On the fifth day, spinal cord samples were collected and
analysed for the expression of IBA1 (microglia), GFAP (astrocytes) and
substance P.
2.8. Statistical analysis
Statistical analyses were performed with Graphpad Prism 7
(GraphPad Software, La Jolla, CA, USA). Individual filaments (Fig. 2)
are presented as mean with S.E.M. and analysed with the two-way
ANOVA followed by Bonferroni's test. Summarised results (Fig. 3 and
Fig. 4) are presented as medians with interquartile ranges and analysed
with the Friedman test followed by Dunn's correction for multiple
comparisons. Immunohistochemistry data are presented as mean of the
sample values with S.E.M. and analysed by one-way ANOVA with
Holm-Sidak correction for multiple comparisons. The difference was
considered significant at P < 0.05.
3. Results
3.1. Experiment 1: chronic intrathecal administration of M3G causes
antinociceptive cross-tolerance to morphine
On day 1, drug-naïve animals showed only a minor response to the
thin (2–15 g) filaments but responded strongly to thick (26–100 g) fi-
laments at the baseline measurements (Fig. 2A) suggesting that the thin
filaments can be used to assess allodynia whereas the responses to thick
filaments represent nociception. Therefore, we analysed the response
rates to thin and thick filament also separately (Fig. 3A–B). On day one,
acute morphine (1.5 μg, intrathecal) did not affect the response rate to
thin filaments but it decreased the response rate to thick filaments
30 min after administration (Fig. 3A and B). In contrast, acute M3G
(5 μg, intrathecal) increased the response rate to thin filaments at
30 min (Fig. 3A). Near-maximum response rate to thick filaments was
already achieved in the baseline measurements and M3G did not affect
it (Fig. 3B).
After administering intrathecal morphine (15 μg) or M3G (5 μg)
twice daily for five days, the baseline values were measured on Day 6,
12 h after the previous drug administration (Fig. 2B). The median re-
sponse rate to the thin von Frey filaments increased from 2 to 15 re-
sponses after chronic morphine administration and from 3 to 13 re-
sponses after chronic M3G administration (Fig. 4A). Neither drug
affected the baseline response rate to thick filaments as maximum re-
sponse was already achieved in baseline measurements on Day 1
(Fig. 4B). After baseline measurements, acute morphine (1.5 μg, in-
trathecal) decreased the response rate to thin filaments, both in the
chronic morphine (at 30, 60 and 120 min) and chronic M3G (at 30 and
60 min) groups (Fig. 3C) indicating relief of allodynia. In contrast, re-
sponse rate to thick filaments showed no significance suggesting de-
velopment of antinociceptive cross-tolerance and tolerance (Fig. 3D).
On Day 7, the baseline values were at the same level as on Day 6 in
both treatment groups (Fig. 4A and B). After administration of a higher
dose of morphine (5 μg, intrathecal), a significant decrease of the
median response rate to thin filaments was seen at 60 min, and 60 and
120 min (Fig. 3E) and thick filaments at 60 min, and 60 and 120 min in
the chronic morphine and M3G treatment groups, respectively
(Fig. 3F). Distribution in response rate to different filaments is pre-
sented in Fig. 2C.
3.2. Experiment 2: chronic intrathecal morphine and M3G increase the
expression of substance P, but not markers of glial activation, in the spinal
cord
3.2.1. Substance P
Compared with the saline-treated group, the area covered by sub-
stance P positive staining in the dorsal horn laminae I–II was increased
by 35% and by 41%, respectively, in the chronic morphine- and the
M3G-treated groups (Fig. 5A). In lamina V, only the effect of morphine
treatment reached statistical significance compared with the saline
group (Fig. 5B). Intrathecal catheterisation itself did not affect sub-
stance P expression in any of the analysed laminae (Fig. 5A–B). Re-
presentative staining images for each group are shown in Fig. 5C.
3.2.2. IBA1
Compared with the intrathecally catheterised animals that received
saline, chronic morphine or M3G treatments did not increase the area of
positive staining of the microglial marker IBA1 or the number of posi-
tive cells in either spinal cord laminae I–II (Fig. 6A and C) or lamina V
(Fig. 6B and D). However, intrathecal catheterisation and saline treat-
ment itself increased the number and the area of IBA1-positive cells
(Fig. 6A and C) in laminae I–II. Representative staining images for each
Fig. 2. The effect of acute and chronic
morphine and M3G on tactile allodynia and
mechanical nociception measured with von
Frey filaments. Effects of acute administra-
tion of intrathecal morphine (1.5 μg) or
morphine-3-glucuronide (M3G, 5 μg) on
day 1 in naïve animals (A). Day 6 (B) and
day 7 (C) show effects of intrathecal mor-
phine (1.5 μg and 5 μg, respectively) in rats
treated with chronic morphine (blue, 15 μg)
or M3G (red, 5 μg). Results are presented as
mean values ± S.E.M. Two-way ANOVA
followed by Bonferroni's test. *P < 0.05,
**P < 0.01 and ***P < 0.001 for
chronically M3G treated group and
#P < 0.05, ##P < 0.01 and
###P < 0.001 for chronically morphine
treated group. n = 7.
K.J. Blomqvist, et al. (XURSHDQ-RXUQDORI3KDUPDFRORJ\

group are shown in Fig. 6E.
3.2.3. GFAP
The number of cells stained by the astrocyte marker GFAP or the
area covered by GFAP positive staining per unit area of tissue was not
significantly changed in the treatment groups, in either laminae I-II or
lamina V (Fig. 7A–D). Representative staining images for each group
are shown in Fig. 7E.
4. Discussion
M3G acutely sensitised animals to mechanical stimulation seen as
an increased response rate to thin filaments but did not have an anti-
nociceptive effect as studied with thick filaments. In contrast, acute
morphine had an antinociceptive effect seen as a decreased response
rate to thick filaments but it did not increase mechanical sensitivity.
Although the acute effects were different, chronic treatment with both
M3G and morphine caused similar development of antinociceptive
tolerance to the morphine, tactile allodynia, and elevated levels of
substance P in the nociceptive laminae of the spinal cord. The reduced
effect of morphine on antinociception after M3G treatment, suggests
development of antinociceptive cross-tolerance. Even though tolerance
developed to the antinociceptive effects of morphine, it could still at-
tenuate tactile allodynia after chronic M3G and morphine treatments.
Fig. 3. Effects of acute administration of intrathecal morphine or morphine-3-glucuronide (M3G) in rats treated with chronic morphine or M3G on tactile allodynia
and mechanical nociception, as measured with thin (2–15 g) and thick (26–100 g) von Frey filaments. Effects of intrathecal morphine (1.5 μg) or (M3G 5 μg) on the
first day in naïve rats are shown for thin (A) and thick (B) filaments. Effects of morphine (1.5 μg) on the sixth day after chronic treatment were tested with thin (C) or
thick (D) filaments, and on the seventh day after morphine (5 μg) with thin (E) or thick (F) filaments. Responses to different forces of the filaments are presented at
baseline (BL) and 30–120 min after drug administration on days 1, 6 and 7. For the thin filaments, which were used to assess tactile allodynia, the sum of responses to
6 filaments (maximum 30) is shown, whereas for the thick filaments, which were used to assess morphine antinociception and development of tolerance, the
maximum of responses was 15 (see Methods). Results are presented as median values ± interquartile range. *P < 0.05, **P < 0.01, and ***P < 0.001 (sig-
nificance compared to BL values, Friedman test followed by Dunn's test for multiple comparisons). n = 7.
Fig. 4. Baseline (BL) values and effects of chronic
administration of intrathecal morphine 15 μg and
morphine-3-glucuronide (M3G) 5 μg on tactile al-
lodynia (thin filaments) and mechanical nocicep-
tion (thick filaments) on Days 1, 6, and 7 are
shown. The median response rates to thin (2–15 g,
A) and thick (26–100 g, B) von Frey filaments are
shown. For the thin filaments, the sum of responses
to 6 filaments (maximum responses 30) is shown,
whereas for the thick filaments the maximum of
responses was 15 (see Methods). Results are pre-
sented as median values ± interquartile range.
*P < 0.05, **P < 0.01, and ***P < 0.001
(significance compared to BL values, Friedman test
followed by Dunn's test for multiple comparisons).
n = 7.
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These results suggest that M3G influences the development of allodynia
and antinociceptive tolerance but do not mediate antinociception.
In line with previous studies (Gong et al., 1992; Komatsu et al.,
2016; Lewis et al., 2010; Roeckel et al., 2017), acute intrathecal M3G
administration caused tactile allodynia (Figs. 2A and 3A). In addition to
this acute effect, both chronic M3G and morphine caused persistent
tactile allodynia after a five-to six-day pretreatment (Fig. 3C and E;
Fig. 4). In line with earlier studies (Angst and Clark, 2006; Ellis et al.,
2016; Yaksh et al., 1986), chronic morphine induced tactile allodynia;
our study adds that chronic M3G also induces tactile allodynia in a
similar manner. Interestingly, acute morphine reversed the tactile al-
lodynia caused by both chronic morphine and M3G. The development
of sensitisation and reversal of it by acute morphine suggest that
chronic M3G might partially modulate similar signaling pathways as
chronic morphine does.
The response rate to thick filaments show that mechanical noci-
ception after acute morphine (1.5 μg) was similar in both morphine-
and M3G-treated groups (Fig. 3D). Also, antinociception was marginal
after a 5-day chronic morphine or M3G treatment compared with Day
1, suggesting development of antinociceptive tolerance and cross-tol-
erance to morphine (Fig. 3D). Although M3G has been proposed to play
a role in morphine-induced tolerance and hyperalgesia (Ekblom et al.,
1993; Smith et al., 1990), we are not aware of any previous studies that
would have shown the effect of chronic M3G pretreatment on the an-
tinociceptive effect of acute morphine. These results suggest that in
addition to sensitisation to mechanical stimuli, M3G can induce anti-
nociceptive cross-tolerance to morphine.
Morphine is known to increase substance P levels and activate glial
cells. In addition to having affinity to the μ receptor, morphine and
M3G have also been suggested to activate microglia and induce opioid
tolerance through the activation of toll-like receptor 4 (Due et al., 2012;
Hutchinson et al., 2010; Lewis et al., 2010; Watkins et al., 2009).
Therefore, we assessed the effects of M3G on the levels of substance P
and glial cell markers. Substance P levels in the dorsal horn of the spinal
cord were increased in a similar fashion after both chronic M3G and
morphine treatments. Acutely administered morphine is known to
inhibit the release of substance P in the dorsal horn of spinal cord, but
the mechanism of the chronic opioid-induced increase of substance P
(Bergstrom et al., 1984; Jokinen et al., 2018) levels is not known al-
though elevated substance P is associated with neuroinflammation,
pain, and opioid-induced hyperalgesia (King et al., 2005; Li and Clark,
2002; Ma et al., 2001). In our study, expression of the microglial marker
IBA1 was not increased in the dorsal horn of the spinal cord compared
with saline-treated animals. However, IBA1 expression was increased in
all intrathecally catheterised groups when compared with intact ani-
mals. It is possible that the catheter-induced inflammatory reaction
blunted the effects of the drugs. Catheter-induced gliosis in the spinal
cord has been reported in one previous study (Mattioli et al., 2012).
Because microglia is activated by substance P (Johnson et al., 2017; Zhu
et al., 2014) and substance P immunoreactivity was increased by M3G
in the present study, microglia may have a role in the observed anti-
nociceptive cross-tolerance between M3G and morphine and sensitisa-
tion to the effect of chronic M3G.
The mechanisms behind M3G-induced mechanical sensitisation and
antinociceptive cross-tolerance with morphine were not investigated in
the present study. M3G was found not to cause hyperalgesia in μ re-
ceptor knockout animals, supporting the role of the μ receptor as
mediator of the pronociceptive effects of M3G. (Roeckel et al., 2017).
The Ki values for M3G and morphine at the μ receptor are 360 nM and
1.8 nM, respectively, indicating low affinity of M3G at the μ receptor
(Mignat et al., 1995). However, M3G concentrations (719 nM) clearly
exceeding this Ki have been measured in the cerebrospinal fluid of
cancer patients receiving high-dose systemic morphine (Goucke et al.,
1994). M3G is very hydrophilic and resides mostly in the extracellular
fluid (Okura et al., 2003). Although cerebrospinal fluid concentrations
are not a direct measure of brain or spinal cord extracellular fluid
concentrations, it is possible that after a long-term high-dose morphine
treatment M3G may have clinically significant effects mediated by the μ
receptor.
Opioid tolerance has been linked to desensitisation and down-reg-
ulation of opioid receptors, activation of the β-arrestin 2 pathway,
cellular adaptive changes such as upregulation of adenylyl cyclase and
Fig. 5. Effects of 4 days of intrathecal morphine
(15 μg) and morphine-3-glucuronide (M3G, 5 μg)
administration on Substance P staining in noci-
ceptive laminae (I–II, A and V, B) of the dorsal horn
in the lumbar spinal cord. Non-catheterised ani-
mals (naïve) and catheterised animals that received
saline were used as controls. Representative images
for substance P-stained samples from the lumbar
spinal cord dorsal horn are shown in C. Results are
presented as mean values ± S.E.M. *P < 0.05,
**P < 0.01, significance between naïve and saline
compared with unpaired t-test and other groups
except naïve by one-way ANOVA followed by
Holm–Sidak's test. n = 8, except n = 4 in the non-
catheterised naïve group. Values are formed from
average of two spinal cord samples per animal.
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changes in MAPK signaling (Al-Hasani and Bruchas, 2011; Bohn et al.,
2000; Rivat and Ballantyne, 2016). In vitro, M3G causes weak Gi acti-
vation but does not activate the β-arrestin 2 pathway suggesting that
M3G activates slightly different signaling pathways compared with
morphine (Roeckel et al., 2017). However, because M3G does not re-
cruit β-arrestin 2, an important signaling pathway for the development
of opioid tolerance (Bohn et al., 2000), the biased agonist properties of
M3G most likely do not explain antinociceptive cross-tolerance between
M3G and morphine. Another explanation could be that similar to
morphine, M3G activates the 6-transmembrane subtype of μ receptors
(Oladosu et al., 2015) or toll-like receptor 4 (Due et al., 2012). Detailed
studies on the mechanism of M3G-induced opioid tolerance and
Fig. 6. Effects of 4 days of intrathecal morphine (15 μg) and morphine-3-glucuronide (M3G, 5 μg) administration on the microglial marker IBA1 in nociceptive
laminae (I–II and V) of spinal cord. The relative area of staining is shown in A–B and the number of IBA1-positive cells per μm2 shown in C–D. Non-catheterised
animals (naïve) and catheterised animals that received saline were used as controls. Representative images for IBA1-stained samples from the lumbar spinal cord
dorsal horn are shown in (E). Results are presented as mean values ± S.E.M. *P < 0.05, **P < 0.01, significance between naïve and saline compared with
unpaired t-test and other groups except naïve by one-way ANOVA followed by Holm–Sidak's test. n = 8, except n = 4 in the non-catheterised naïve group. Two
samples per animal were analysed and the average used.
K.J. Blomqvist, et al. (XURSHDQ-RXUQDORI3KDUPDFRORJ\

hyperalgesia are needed.
In conclusion, chronic intrathecal M3G treatment leads to persistent
tactile allodynia and antinociceptive cross-tolerance to morphine in a
similar way as chronic intrathecal morphine treatment does. In
addition, M3G-induced mechanical sensitisation could be reversed by
morphine. M3G increased spinal cord levels of substance P suggesting
that the excitatory effect of substance P may have a role in M3G-in-
duced allodynia.
Fig. 7. Effects of 4 days of intrathecal morphine (15 μg) and morphine-3-glucuronide (M3G, 5 μg) administration on the astrocyte marker GFAP in nociceptive
laminae (I–II and V) of spinal cord. The relative area of staining is shown in A–B and the number of GFAP-positive cells per μm2 shown in C–D. Non-catheterised
animals (naïve) and catheterised animals that received saline were used as controls. Representative images for GFAP-stained samples from the lumbar spinal cord
dorsal horn are shown in (E). Results are presented as mean values ± S.E.M., statistical comparison between naïve and saline compared with unpaired t-test and
other groups except naïve by one-way ANOVA followed by Holm–Sidak's test showed no significance. n = 8, except n = 4 in the non-catheterised naïve group. Two
samples per animal were analysed and the average used.
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